查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790404

美國抗體藥物複合體市場規模、佔有率和趨勢分析報告：按應用、技術、產品、目標和細分市場預測，2025 年至 2030 年

U.S. Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer), By Technology, By Product, By Target, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國抗體藥物複合體市場摘要

預計 2024 年美國抗體藥物複合體市場價值將達到 71.5 億美元，2025 年至 2030 年期間的複合年成長率為 4.9%，到 2030 年將達到 106 億美元。這是由癌症發生率的上升和對低毒性有效藥物的需求不斷成長所推動的。

此外，製藥和生技公司正大力投資抗體藥物複合體(ADC) 的研發，推動市場成長。美國癌症患者數量的增加極大地推動了對 ADC 等標靶治療的需求。據美國癌症協會稱，到 2024 年，美國將診斷出 200 多萬例新癌症病例。由於人口老化、生活方式的改變和診斷能力的提高等各種因素，癌症患者的數量正在增加。 ADC 提供了一種高度針對性的方法，將細胞毒藥物直接輸送到癌細胞並最大限度地減少對健康組織的損害。這種精確性使得 ADC 比傳統化療更受歡迎，特別是對於難治性癌症。

資金籌措的增加正在加速ADC的開發，使其適應症範圍超越腫瘤學。例如，2025年3月，專注於研發用於癌症治療的多負載ADC的生物技術公司Kario Therapeutics在獲得由Frazier Life Sciences主導的1.87億美元A輪資金籌措後宣布推出。 Kario計劃利用這筆資金推進其HER2靶向雙負載ADC的臨床驗證。

抗體製造、連接體穩定性和細胞毒性有效載荷領域的不斷創新，正在推動高效、更安全的 ADC 的開發。 2024 年 9 月，默克推出了 Möbius ADC 反應器，這是一款一次性反應器，旨在生產能夠精準靶向並清除癌細胞，同時不損害健康組織的 ADC。

併購低迷，知名製藥公司專注於收購在ADC技術方面擁有專長的公司，以增強其腫瘤產品組合。例如，強生服務公司於2024年3月收購了Ambrx Biopharma, Inc.，該公司擁有專有的合成生物學技術平台，用於開發和設計下一代ADC，預計這些ADC將帶來差異化的固體癌治療方案，從而改善患者的生活。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗體藥物複合體市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關市場展望
  • 產業價值鏈分析
  • 法律規範
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
    • 行業機會
  • 產業分析工具
    • 波特五力分析
    • 宏觀環境分析

第4章：美國抗體藥物複合體市場：應用估計與趨勢分析

  • 細分儀表板
  • 美國抗體藥物複合體市場：應用變化分析和市場佔有率（2024 年和 2030 年）
  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 乳癌
  • 尿路上皮癌和膀胱癌
  • 其他癌症

第5章美國抗體藥物複合體市場：產品估計與趨勢分析

  • 細分儀表板
  • 美國抗體藥物複合體市場：2024 年和 2030 年產品變化分析和市場佔有率
  • 門頭
  • 恩格爾圖
  • ADCETRIS
  • 帕德切夫
  • 特羅德爾維
  • 波利維
  • 其他

第6章：美國抗體藥物複合體市場：目標估計與趨勢分析

  • 細分儀表板
  • 美國抗體藥物複合體市場：2024 年及 2030 年標靶變異分析及市場佔有率
  • HER2
  • CD22
  • CD30
  • 其他

第7章：美國抗體藥物複合體市場：技術評估與趨勢分析

  • 細分儀表板
  • 美國抗體藥物複合體市場：2024 年和 2030 年技術變革分析和市場佔有率
  • 類型
    • 可裂解接頭
    • 不可切割的連接子
    • 無連結
  • 連結器技術類型
    • VC
    • Sulfo-SPDB
    • VA
    • Hydrazone
    • 其他
  • 有效載荷技術
    • MMAE
    • MMAF
    • DM4
    • 喜樹鹼
    • 其他

第8章美國抗體藥物複合體市場－競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖
  • Position Analysis, 2024
  • 戰略地圖
    • 擴張
    • 合併與收購
    • 夥伴關係和合作
    • 新產品發布
    • 研究與開發
  • 公司簡介
    • Seagen, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Gilead Sciences, Inc.
    • Daiichi Sankyo Company Ltd.
    • GlaxoSmithKline Plc
    • Astellas Pharma, Inc.
    • ADC Therapeutics SA
Product Code: GVR-4-68040-670-8

U.S. Antibody Drug Conjugates Market Summary

The U.S. antibody drug conjugates market size was valued at USD 7.15 billion in 2024 and is projected to reach USD 10.60 billion by 2030, growing at a CAGR of 4.9% from 2025 to 2030. This can be attributed to the increasing incidence of cancer cases and increased demand for low-toxicity & effective drugs.

Also, pharmaceutical and biotech companies are investing heavily in researching and developing antibody drug conjugates (ADCs), propelling market growth. The growing number of cancer cases in the U.S. significantly fuels demand for targeted therapies like ADCs. According to the American Cancer Society Inc., in 2024, over 2 million new cancer cases were detected in the U.S. The number of cancer cases is rising due to various factors such as aging populations, lifestyle changes, and improved diagnostic capabilities. ADCs offer a highly focused approach that delivers cytotoxic drugs straight to cancer cells, reducing damage to healthy tissues. This accuracy makes ADCs preferred to traditional chemotherapy, especially for challenging cancers.

The rising funding is accelerating the development of ADCs across a wider range of indications beyond oncology. For instance, in March 2025, Callio Therapeutics, a biotechnology firm dedicated to multi-payload ADCs aimed at cancer treatment, declared its launch after securing USD 187 million in Series A funding led by Frazier Life Sciences. Callio intends to use the funds to progress clinical proof-of-concept for its HER2-targeted dual-payload ADC.

The rising technological innovations in antibody manufacturing, linker stability, and cytotoxic payloads have led to the development of effective and safer ADCs. In September 2024, Merck launched the Mobius ADC Reactor, a single-use reactor designed to manufacture ADCs that precisely target and eliminate tumor cells while leaving healthy tissue unharmed.

Mergers and acquisitions (M&A) are moderate, with prominent pharmaceutical companies focusing on acquiring companies with expertise in ADC technologies to improve their oncology portfolios. For instance, in March 2024, Johnson & Johnson Services, Inc. acquired Ambrx Biopharma, Inc. It has a proprietary synthetic biology technology platform to develop and design next-generation ADC. This is expected to deliver differentiated solid tumor treatment to improve the lives of patients'.

U.S. Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibody drug conjugates market report based on application, product, target, and technology:

  • Application (Revenue, USD Million, 2018 - 2030)
  • Blood Cancer
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
  • Breast Cancer
  • Urothelial Cancer & Bladder Cancer
  • Other Cancer
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others
  • Target Outlook (Revenue, USD Million, 2018 - 2030)
  • HER2
  • CD22
  • CD30
  • Others
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Type
    • Cleavable Linker
    • Non-cleavable Linker
    • Linkerless
  • Linker Technology Type
    • VC
    • Sulfo-SPDB
    • VA
    • Hydrazone
    • Others
  • Payload Technology
    • MMAE
    • MMAF
    • DM4
    • Camptothecin
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Antibody Drug Conjugates Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related Market Outlook
  • 3.2. Industry Value Chain Analysis
  • 3.3. Regulatory Framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
    • 3.4.3. Industry Challenges
    • 3.4.4. Industry Opportunities
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. Macro-environmental Analysis

Chapter 4. U.S. Antibody Drug Conjugates Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Antibody Drug Conjugates Market: Application Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Blood Cancer
    • 4.3.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Leukemia
      • 4.3.2.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Lymphoma
      • 4.3.3.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Multiple Myeloma
      • 4.3.4.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Urothelial Cancer & Bladder Cancer
    • 4.5.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Cancer
    • 4.6.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Antibody Drug Conjugates Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Antibody Drug Conjugates Market: Product Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Kadcyla
    • 5.3.1. Kadcyla Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Enhertu
    • 5.4.1. Enhertu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Adcetris
    • 5.5.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Padcev
    • 5.6.1. Padcev Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Trodelvy
    • 5.7.1. Trodelvy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Polivy
    • 5.8.1. Polivy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Antibody Drug Conjugates Market: Target Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Antibody Drug Conjugates Market: Target Movement Analysis & Market Share, 2024 & 2030
  • 6.3. HER2
    • 6.3.1. HER2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CD22
    • 6.4.1. CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CD30
    • 6.5.1. CD30 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Antibody Drug Conjugates Market: Technology Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Antibody Drug Conjugates Market: Technology Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Type
    • 7.3.1. Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Cleavable Linker
      • 7.3.2.1. Cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Non-cleavable Linker
      • 7.3.3.1. Non-cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Linkerless
      • 7.3.4.1. Linkerless Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Linker Technology Type
    • 7.4.1. Linker Technology Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. VC
      • 7.4.2.1. VC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Sulfo-SPDB
      • 7.4.3.1. Sulfo-SPDB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. VA
      • 7.4.4.1. VA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Hydrazone
      • 7.4.5.1. Hydrazone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Others
      • 7.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Payload Technology
    • 7.5.1. Payload Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. MMAE
      • 7.5.2.1. MMAE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. MMAF
      • 7.5.3.1. MMAF Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. DM4
      • 7.5.4.1. DM4 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Camptothecin
      • 7.5.5.1. Camptothecin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Others
      • 7.5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Antibody Drug Conjugates Market - Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map
  • 8.4. Position Analysis, 2024
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research and Development
  • 8.6. Company Profiles
    • 8.6.1. Seagen, Inc.
      • 8.6.1.1. Participant's overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Recent developments
    • 8.6.2. Takeda Pharmaceutical Company Ltd.
      • 8.6.2.1. Participant's overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Recent developments
    • 8.6.3. AstraZeneca
      • 8.6.3.1. Participant's overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Recent developments
    • 8.6.4. F. Hoffmann-La Roche Ltd.
      • 8.6.4.1. Participant's overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Recent developments
    • 8.6.5. Pfizer, Inc.
      • 8.6.5.1. Participant's overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Recent developments
    • 8.6.6. Gilead Sciences, Inc.
      • 8.6.6.1. Participant's overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Recent developments
    • 8.6.7. Daiichi Sankyo Company Ltd.
      • 8.6.7.1. Participant's overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Recent developments
    • 8.6.8. GlaxoSmithKline Plc
      • 8.6.8.1. Participant's overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Recent developments
    • 8.6.9. Astellas Pharma, Inc.
      • 8.6.9.1. Participant's overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Recent developments
    • 8.6.10. ADC Therapeutics SA
      • 8.6.10.1. Participant's overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Recent developments

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. antibody drug conjugates market 2018 - 2030 (USD Million)
  • Table 3 U.S. antibody drug conjugates market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 4 U.S. antibody drug conjugates market estimates and forecasts by product, 2018 - 2030 (USD Million)
  • Table 5 U.S. antibody drug conjugates market estimates and forecasts by target, 2018 - 2030 (USD Million)
  • Table 6 U.S. antibody drug conjugates market estimates and forecasts by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 QFD Modeling for Market Share Assessment
  • Fig. 6 Information Procurement
  • Fig. 7 Market Formulation and Validation
  • Fig. 8 Data Validating & Publishing
  • Fig. 9 Market Segmentation & Scope
  • Fig. 10 U.S. Antibody Drug Conjugates Market Snapshot
  • Fig. 11 Segment Snapshot (1/2)
  • Fig. 12 Segment Snapshot (1/2)
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent market outlook
  • Fig. 15 U.S. Antibody Drug Conjugates Market Value, 2024 (USD Million)
  • Fig. 16 U.S. Antibody Drug Conjugates Market - Value Chain Analysis
  • Fig. 17 U.S. Antibody Drug Conjugates Market - Market Dynamics
  • Fig. 18 U.S. Antibody Drug Conjugates Market - PORTER's Analysis
  • Fig. 19 U.S. Antibody Drug Conjugates Market - PESTEL Analysis
  • Fig. 20 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
  • Fig. 21 U.S. Antibody Drug Conjugates Market Share, by Application, 2024 & 2030
  • Fig. 22 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
  • Fig. 23 Blood Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Leukemia Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Lymphoma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Multiple Myeloma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Breast Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Urothelial Cancer & Bladder Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Other Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Product: Key Takeaways
  • Fig. 31 U.S. Antibody Drug Conjugates Market Share, by Product, 2024 & 2030
  • Fig. 32 Kadcyla Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Enhertu Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Adcetris Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Padcev Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Trodelvy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Polivy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Target: Key Takeaways
  • Fig. 40 U.S. Antibody Drug Conjugates Market Share, by Target, 2024 & 2030
  • Fig. 41 HER2 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 CD22 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 CD30 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Technology: Key Takeaways
  • Fig. 46 U.S. Antibody Drug Conjugates Market Share, by Technology, 2024 & 2030
  • Fig. 47 Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Non-cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Linkerless Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Linker Technology Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 VC Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Sulfo-SPDB Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 VA Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Hydrazone Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Payload Technology Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 MMAE Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 MMAF Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 DM4 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Camptothecin Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key Company Categorization
  • Fig. 64 Company Market Positioning
  • Fig. 65 Strategy Mapping